{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:39:44Z","timestamp":1793090384173,"version":"4.5.0"},"reference-count":168,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T00:00:00Z","timestamp":1568246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The interleukin-3 receptor alpha chain (IL-3R), more commonly referred to as CD123, is widely overexpressed in various hematological malignancies, including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia, hairy cell leukemia, Hodgkin lymphoma and particularly, blastic plasmacytoid dendritic neoplasm (BPDCN). Importantly, CD123 is expressed at both the level of leukemic stem cells (LSCs) and more differentiated leukemic blasts, which makes CD123 an attractive therapeutic target. Various agents have been developed as drugs able to target CD123 on malignant leukemic cells and on the normal counterpart. Tagraxofusp (SL401, Stemline Therapeutics), a recombinant protein composed of a truncated diphtheria toxin payload fused to IL-3, was approved for use in patients with BPDCN in December of 2018 and showed some clinical activity in AML. Different monoclonal antibodies directed against CD123 are under evaluation as antileukemic drugs, showing promising results either for the treatment of AML minimal residual disease or of relapsing\/refractory AML or BPDCN. Finally, recent studies are exploring T cell expressing CD123 chimeric antigen receptor-modified T-cells (CAR T) as a new immunotherapy for the treatment of refractory\/relapsing AML and BPDCN. In December of 2018, MB-102 CD123 CAR T developed by Mustang Bio Inc. received the Orphan Drug Designation for the treatment of BPDCN. In conclusion, these recent studies strongly support CD123 as an important therapeutic target for the treatment of BPDCN, while a possible in the treatment of AML and other hematological malignancies will have to be evaluated by in the ongoing clinical studies.<\/jats:p>","DOI":"10.3390\/cancers11091358","type":"journal-article","created":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T10:56:06Z","timestamp":1568285766000},"page":"1358","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":147,"title":["CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7900-8942","authenticated-orcid":false,"given":"Ugo","family":"Testa","sequence":"first","affiliation":[{"name":"Department of Oncology, Istituto Superiore di Sanit\u00e0, Viale Regina Elena 299, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Pelosi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Istituto Superiore di Sanit\u00e0, Viale Regina Elena 299, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germana","family":"Castelli","sequence":"additional","affiliation":[{"name":"Department of Oncology, Istituto Superiore di Sanit\u00e0, Viale Regina Elena 299, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,9,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Hartman, L., and Metzler, K.H. (2019). Clonal hematopoiesis and preleukemia\u2013Genetics, biology, and clinical implications. Genes Chromosom. Cancer.","DOI":"10.1002\/gcc.22756"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Valent, P., Kern, W., Hoermann, G., Feenstra, J.M., Sotlar, K., and Pfeilstocker, M. (2019). Clonal hematopoiesis with oncogenic potential (CHOP): Separation from CHIP and roads to AML. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030789"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"926","DOI":"10.6004\/jnccn.2017.0116","article-title":"Acute myeloid leukemia, version 3.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Tallman","year":"2017","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision in the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2016.71.2208","article-title":"Genomics of acute myeloid leukemia diagnosis and pathways","volume":"35","author":"Bullinger","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/asheducation-2017.1.37","article-title":"Classification and risk assessment in AML: Integrating cytogenetics and molecular profiling","volume":"2017","author":"Moarii","year":"2017","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature22993","article-title":"Tracing the origins of relapse in acute myeloid leukaemia to stem cells","volume":"547","author":"Shlush","year":"2017","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s41375-018-0326-3","article-title":"CD34+CD38\u2212 leukemic stem cell frequency to predict outcome in acute myeloid leukemia","volume":"33","author":"Zeijlemaker","year":"2019","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41375-018-0227-5","article-title":"The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia","volume":"33","author":"Duployez","year":"2019","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/s41375-019-0386-z","article-title":"A novel method for detecting the cellular stemness state in normal and leukemic human hematopoietic cells can predict disease outcome and drug sensitivity","volume":"33","author":"Yassin","year":"2019","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Potter, N., Mizaki-Moud, F., Ermini, L., Titley, J., Mijaraghavan, G., Papaemmanuil, E., Campbell, P., Gribben, J., Taussig, D., and Graeves, M. (2019). Single cell analysis of clonal architecture in acute myeloid leukemia. Leukemia.","DOI":"10.1038\/s41375-018-0319-2"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1182\/blood-2018-05-852822","article-title":"Genomic landscape and clonal evolution of acute myeloid leukemia with t (8;21): An international study on 331 patients","volume":"133","author":"Christen","year":"2019","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/blood-2018-03-837781","article-title":"Clonal interference of signaling mutations worsens prognostic in core-binding factor acute myeloid leukemia","volume":"132","author":"Itzykson","year":"2018","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1158\/1078-0432.CCR-17-2344","article-title":"Evolution of cytogenetically normal acute myeloid leukemia during therapy and relapse: An exome sequencing study of 50 patients","volume":"24","author":"Greif","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1038\/s41467-019-09745-2","article-title":"Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation","volume":"10","author":"Cocciardi","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1038\/s41375-018-0368-6","article-title":"Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis","volume":"33","author":"Loberg","year":"2019","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia","volume":"9","author":"MacMahon","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","article-title":"Hematopoietic stem cell transplantation for patients with AML in first complete remission","volume":"127","author":"Cornelissen","year":"2016","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Rautenberg, C., Germing, U., Haas, R., Kobbe, G., and Schroeder, T. (2019). Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: Prevention, detection, and treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20010228"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1182\/blood-2018-10-846824","article-title":"Mechanisms of immune escape after allogeneic hematopoietic cell transplantation","volume":"133","author":"Zeiser","year":"2019","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.bbmt.2011.07.012","article-title":"Genome-wide profiling in AML patients relapsing after allogeneic hematopoietic cell transplantation","volume":"17","author":"Waterhouse","year":"2011","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1182\/bloodadvances.2016000760","article-title":"Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia","volume":"1","author":"Quek","year":"2016","journal-title":"Blood Adv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e581","DOI":"10.3324\/haematol.2018.193102","article-title":"Relapse of acute myeloid leukemia after allogeneic stem cell transplantation is associated with gain of WT1 alterations and high mutation load","volume":"103","author":"Vosberg","year":"2018","journal-title":"Haematologica"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Taffalori","year":"2019","journal-title":"Nat Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/bloodadvances.2019000445","article-title":"Recurrent genetic HLA loss in HLA relapsed after matched unrelated allogeneic hematopoietic cell transplantation","volume":"3","author":"Jan","year":"2019","journal-title":"Blood Adv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/s41467-019-08871-1","article-title":"Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT","volume":"10","author":"Noviello","year":"2019","journal-title":"Nat Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1200\/JCO.2018.79.2184","article-title":"Role of donor clonal hematopoiesis in allogeneic hematopoietic stem cell transplantation","volume":"37","author":"Frick","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"98962","DOI":"10.1172\/jci.insight.98962","article-title":"Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant","volume":"3","author":"Jacoby","year":"2018","journal-title":"JCI Insight"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-019-0170-3","article-title":"Late relapse in acute myeloid leukemia (AML): Clonal evolution of therapy-related leukemia?","volume":"9","author":"Yilmaz","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ng.3742","article-title":"Dynamics of clonal evolution in myelodysplastic syndromes","volume":"49","author":"Makishima","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41591-018-0267-4","article-title":"Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level","volume":"25","author":"Chen","year":"2019","journal-title":"Nat. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1600-065X.2012.01164.x","article-title":"The GM-CSF\/IL-3\/IL-5 cytokine receptor family: From ligand recognition to initiation of signaling","volume":"250","author":"Broughton","year":"2012","journal-title":"Immunol. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cytogfr.2013.03.002","article-title":"Signaling of the \u03b2c family of cytokines","volume":"24","author":"Hercus","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3109\/08977194.2011.649919","article-title":"The GM-CSF receptor family: Mechanism of activation and implications for disease","volume":"30","author":"Hercus","year":"2012","journal-title":"Growth Factors"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41467-017-02633-7","article-title":"A dual role for the N-terminal domain of the IL-3 receptor in cell signaling","volume":"9","author":"Broughton","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_43","first-page":"65","article-title":"Interleukin-3 and hematopoiesis","volume":"51","author":"Ihle","year":"1992","journal-title":"Chem. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.cyto.2015.02.005","article-title":"The \u03b2c receptor family-structural insights and their functional implications","volume":"74","author":"Broughton","year":"2015","journal-title":"Cytokine"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1182\/blood.V88.7.2458.bloodjournal8872458","article-title":"Hematopoiesis in mice lacking the entire granulocyte-macrophage colony-stimulating factor\/interleukin-3\/interleukin-5 functions","volume":"88","author":"Nishinakamura","year":"1996","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1172\/JCI116534","article-title":"Interleukin-3 stimulates proliferation and triggers endothelial leukocyte adhesion molecule 1 gene activation of human endothelial cells","volume":"91","author":"Brizzi","year":"1993","journal-title":"J. Clin. Investig."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2050-7771-2-4","article-title":"CD123 is a membrane biomarker and a therapeutic target in hematologic malignancies","volume":"2","author":"Testa","year":"2014","journal-title":"Biomark. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"key":"ref_49","first-page":"1261","article-title":"Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies","volume":"86","author":"Munoz","year":"2001","journal-title":"Haematologica"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2002-03-0852","article-title":"Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity and poor prognosis","volume":"100","author":"Testa","year":"2002","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/bloodadvances.2016002931","article-title":"High CD123 levels enhance proliferation is response to IL-3, but reduce chemotaxis by downregulating CXCR4 expression","volume":"1","author":"Wittwer","year":"2017","journal-title":"Blood Adv."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s12185-019-02616-y","article-title":"Impact of CD123 expression, analyzed by immunohistochemistry, on clinical outcomes in patients with acute myeloid leukemia","volume":"109","author":"Arai","year":"2019","journal-title":"Int. J. Hematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/sj.leu.2403224","article-title":"Interleukin-3 receptor in acute leukemia","volume":"18","author":"Testa","year":"2004","journal-title":"Leukemia"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1365-2141.2008.07491.x","article-title":"Interleukin (IL)-3\/granulocyte macrophage-colony stimulating factor \/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukemias with mutated FMS-related tyrosine 3 kinase receptor","volume":"144","author":"Riccioni","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1365-2141.2011.08577.x","article-title":"Immunophenotypic features of acute myeloid leukemia patients exhibiting high Flt3 expression not associated with mutations","volume":"153","author":"Riccioni","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/PAI.0b013e318261a342","article-title":"CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations","volume":"21","author":"Pillai","year":"2013","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_57","first-page":"142","article-title":"CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping","volume":"96","author":"Brass","year":"2019","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-016-0292-z","article-title":"Immunoprofiling of leukemic stem cells CD34+\/CD38\u2212\/CD123+ delineate FLT3\/ITD-positive clones","volume":"9","author":"Gillis","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1158\/1078-0432.CCR-14-3186","article-title":"A leukemia-associated CD34\/CD123\/CD25\/CD99+ immunophenotype identifies FLT3-mutated clones in acute myeloid leukemia","volume":"21","author":"Angelini","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41379-019-0263-3","article-title":"Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group","volume":"32","author":"Weinberg","year":"2019","journal-title":"Mod. Pathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1182\/blood.V98.8.2301","article-title":"Nuclear factor B is constitutively activated in primitive acute human acute myelogenous leukemia cells","volume":"98","author":"Guzman","year":"2011","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s00277-012-1501-7","article-title":"Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia","volume":"91","author":"Hwang","year":"2012","journal-title":"Ann. Hematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3324\/haematol.2011.047894","article-title":"High levels of CD34+CD38low\/CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia","volume":"96","author":"Vergez","year":"2011","journal-title":"Haematologica"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.bcmd.2015.07.015","article-title":"Targeting LSCs through membrane antigens selectively or preferentially expressed in these cells","volume":"55","author":"Pelosi","year":"2015","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41375-018-0279-6","article-title":"Histone deacetylase inhibitor targets CD123\/CD47 positive cells and reverse chemoresistant phenotype in acute myeloid leukemia","volume":"33","author":"Yan","year":"2019","journal-title":"Leukemia"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"34056","DOI":"10.18632\/oncotarget.26118","article-title":"Survival outcomes of CD34+CD38\u2212 LSCs and their expression of CD123 in adult AML patients","volume":"9","author":"Zahran","year":"2018","journal-title":"Oncotarget"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/bloodadvances.2018016378","article-title":"Evaluating measurable residual disease in acute myeloid leukemia","volume":"2","author":"Ravandi","year":"2018","journal-title":"Blood Adv."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivet","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"98561","DOI":"10.1172\/jci.insight.98561","article-title":"Universal monitoring of minimal residual disease in acute myeloid leukemia","volume":"3","author":"Song","year":"2018","journal-title":"JCI Insights"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Grob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Venugopal, S., Zhou, S., Jamal, S., Lane, A.A., and Mascarenhas, J. (2019). Blastic plasmocytoid dendritic cell neoplasm. Clin. Lymphoma Myeloma Leuk., in press.","DOI":"10.1016\/j.clml.2019.06.002"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Sapienza, M.R., Pileri, A., Derenzini, E., Melle, F., Motta, G., Fiori, S., Calleri, A., Pimpinelli, N., Tabanelli, V., and Pileri, S. (2019). Blastic plasmacytoid dendritic cell neoplasm: State of the arty and prospects. Cancers, 11.","DOI":"10.3390\/cancers11050595"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7326\/0003-4819-131-7-199910050-00035","article-title":"CD123hi dendritic cell lymphoma: An unusual case of non-Hodgkin lymphoma","volume":"131","author":"Lucio","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1182\/blood.V97.10.3210","article-title":"Identification of a leukemic counterpart of the plasmacytoid dendritic cells","volume":"97","author":"Chaperot","year":"2001","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2012-08-448613","article-title":"Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: A retrospective study from the European group and bone marrow transplantation","volume":"121","author":"Dietrich","year":"2013","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3324\/haematol.2012.072645","article-title":"Blast plasmacytoid dendritic cell neoplasm with leukemic presentation: An Italian multicenter study","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica"},{"key":"ref_79","first-page":"303","article-title":"The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes","volume":"89","author":"Matutes","year":"2004","journal-title":"Haematologica"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1309\/AJCPKUM9J4IXCWEU","article-title":"Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia","volume":"136","author":"Venkatam","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.leukres.2012.11.021","article-title":"Distinguishing hairy cell leukemia variant from hairy cell leukemia: Development and validation of diagnostic criteria","volume":"37","author":"Shao","year":"2013","journal-title":"Leuk. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2016-01-689422","article-title":"Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia","volume":"129","author":"Grever","year":"2017","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/cyto.b.20561","article-title":"Flow cytometric analysis of CD123 is useful for immunophenotyping classical Hodgkin lymphoma","volume":"80B","author":"Fromm","year":"2011","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3324\/haematol.2008.000299","article-title":"Overexpression of CD123 correlates with hyperdiploid genotype in acute lymphoblastic leukemia","volume":"94","author":"Djokic","year":"2009","journal-title":"Haematologica"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1309\/AJCPO4DS0GTLSOEI","article-title":"Distinct expression patternbs of CD123 and CD34 on normal bone marrow B-cell precursors (\u201chematogenes\u201d) and B lymphoblastic leukemia blasts","volume":"132","author":"Hassanein","year":"2009","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1182\/blood-2010-12-324004","article-title":"New markers for minimal residual disease detection in acute lymphoblastic leukemia","volume":"117","author":"Song","year":"2011","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3324\/haematol.2018.205252","article-title":"CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia","volume":"104","author":"Angelova","year":"2019","journal-title":"Haematologica"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/j.clml.2019.03.012","article-title":"Study of the prognostic value of aberrant antigen in patients with acute B lymphocytic leukemia","volume":"19","author":"Liu","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/sj.leu.2401743","article-title":"Diphteria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias","volume":"14","author":"Frankel","year":"2000","journal-title":"Leukemia"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1080\/10428190410001663572","article-title":"Toxicilogy and pharmacokinetics of DT388IL3, a fusion protein consisting of a truncated diphteria toxin (DT388) linked to human interleukin 3 (IL3) in cynomolgous monkeys","volume":"45","author":"Cohen","year":"2004","journal-title":"Leuk. Lymphoma"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00262-004-0643-4","article-title":"Safety evaluation of DT388IL3, a diphteria toxin\/interleukin 3 fusion protein, in cynomolgus monkey","volume":"54","author":"Cohen","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2005-02-0540","article-title":"Diphteria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression","volume":"106","author":"Testa","year":"2005","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood-2006-04-013813","article-title":"Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice","volume":"108","author":"Yalcintepe","year":"2006","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1158\/1078-0432.CCR-05-2070","article-title":"Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors","volume":"12","author":"Hogge","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3324\/haematol.2014.111740","article-title":"In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasms to SL-401, an interleukin-3 receptor targeted biologic agent","volume":"100","author":"Roggy","year":"2015","journal-title":"Haematologica"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/blood-2014-04-566737","article-title":"Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients","volume":"124","author":"Frankel","year":"2014","journal-title":"Blood"},{"key":"ref_97","first-page":"1298","article-title":"Results of pivotal phaser 2 trial of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)","volume":"130","author":"Pemmaraju","year":"2017","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-018-0604-6","article-title":"First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: Report of three cases","volume":"11","author":"Sun","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.3324\/haematol.2018.188193","article-title":"The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+ CD123+ cells from acute myeloid leukemia\/myelodysplastic syndrome patients and healthy donors","volume":"103","author":"Mani","year":"2018","journal-title":"Haematologica"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/10428190701799035","article-title":"Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia","volume":"49","author":"Frankel","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood.V128.22.215.215","article-title":"Results from ongoing phase 2 trial of SL-401 as consolidation therapy in patients with acute myeloid leukemia (AML) in remission with high relapse risk including minimal residual disease (MRD)","volume":"128","author":"Lane","year":"2016","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood.V130.Suppl_1.797.797","article-title":"Resistance to SL-401 in AML and BPDCN is associated with loss of diphtamide synthesis pathway enzyme DPH1 and is reversible by azacytidine","volume":"170","author":"Stephansky","year":"2017","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Tagami, K., Pastika, T., Stephansky, J., Ghandi, M., Christie, A.L., Jones, K.L., Johnson, C.A., Lindsay, A.W., Brooks, C.L., and Letai, A. (2019). DNA methyltransferase inhibition overcomes diphtamide pathway deficiencies underlying CD123-targeted treatment resistance. J. Clin. Investig.","DOI":"10.1172\/JCI128571"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1038\/leu.2017.135","article-title":"A novel agent SL-401 induces anti-myeloma activity by targeting plasmocytoid dendritic cells, osteoclastogenesis and cancer stem-like cells","volume":"31","author":"Ray","year":"2017","journal-title":"Leukemia"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1182\/blood.V128.22.5696.5696","article-title":"Results from ongoing phase 1\/2 trial of SL-401 in combination with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma","volume":"128","author":"Htut","year":"2016","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.1182\/blood.V124.21.5577.5577","article-title":"Expression of CD123 (IL-3R alpha), a therapeutic target of SL-401, on myeloproliferative neoplasms","volume":"124","author":"Lashjo","year":"2014","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1182\/blood.V128.22.4245.4245","article-title":"Results from ongoing phase 2 trial of SL-401 in patients with advanced, high-risk myeloproliferative neoplasms including chronic myelomonocytic leukemia","volume":"128","author":"Patnaik","year":"2016","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1182\/blood-2018-99-119302","article-title":"Results from ongoing phase 1\/2 clinical trial of tagraxopusp (SL-401) in patients with relapsed\/refractory chronic myelomonocytic leukemia (CMML)","volume":"132","author":"Patnaik","year":"2018","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1182\/blood-2018-99-119201","article-title":"Results from ongoing phase 1\/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed\/refractory myelofibrosis","volume":"132","author":"Pemmaraju","year":"2018","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Lucas, N., Duchmann, M., Rameau, P., Noel, F., Michea, P., Saada, V., Kosmider, O., Pierron, G., Fernandez-Zapico, M.E., and Howard, M.T. (2019). Biology and prognostic impact of clonal plasmocytoid dendritic cells in chronic myelomonocytic leukemia. Leukemia.","DOI":"10.1038\/s41375-019-0447-3"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/bjh.12978","article-title":"SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukemic cells and stem cells in advanced chronic myeloid leukemia","volume":"166","author":"Frolova","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1158\/1078-0432.CCR-16-1904","article-title":"Antileukemia efficacy and mechanisms of action of SL-101, a novel anti-CD123 antibody conjugate, in acute myeloid leukemia","volume":"23","author":"Han","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood.V87.1.83.83","article-title":"Monoclonal antobody 7G3 recognizes the N-terminal domain of the human interleukin-3 (IL-3) receptor alpha-chain and functions as a specific receptor antagonist","volume":"87","author":"Sun","year":"1996","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.stem.2009.04.018","article-title":"Monoclonal-antibody mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemia stem cells","volume":"5","author":"Jin","year":"2009","journal-title":"Cell Stem Cell"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1182\/blood.V120.21.3598.3598","article-title":"CSL362: A monoclonal antibody to human interleukin 3 receptor (CD123), optimized for NK cell-mediated cytotoxicity of AML stem cells","volume":"120","author":"Busfield","year":"2012","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1182\/blood.V120.21.1524.1524","article-title":"Pharmacodynamic activity and preclinical safety of CSL362, a novel humanized, affinity-matured monoclonal antibody against human interleukin 3 receptor","volume":"120","author":"Herzog","year":"2012","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1182\/blood.V120.21.3599.3599","article-title":"A neutralizing antibody (CSL362) against the interleukin-3 receptor alpha with CSL362 augments the efficacy of a cytabarine\/daunorubicin induction-type therapy in preclinical xenograft models of acute myelogenous leukemia","volume":"120","author":"Lee","year":"2012","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1182\/blood-2012-12-475194","article-title":"Monoclonal antobody targeting IL-3 receptor alpha with CSL 362 effectively depletes CML progenitor and stem cells","volume":"123","author":"Nievergall","year":"2014","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1038\/leu.2014.128","article-title":"Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC","volume":"28","author":"Busfield","year":"2014","journal-title":"Leukemia"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.celrep.2014.06.038","article-title":"Dual mechanism of interleukin-3 receptor blockade by anti-cancer antibody","volume":"8","author":"Broughton","year":"2014","journal-title":"Cell Rep."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3324\/haematol.2014.113092","article-title":"Efficacy of an Fc-modified anti-CD123 antibody CSL362 combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice","volume":"100","author":"Lee","year":"2015","journal-title":"Haematologica"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1038\/bcj.2017.52","article-title":"CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission","volume":"7","author":"Xie","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.3109\/10428194.2014.956316","article-title":"A phase I study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia","volume":"56","author":"He","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"abst. 120","DOI":"10.1182\/blood.V124.21.120.120","article-title":"First in man, phase I study of CSL362 (anti-IL3R\u03b1\/CD123) monoclonal antibody in patients with CD123+ acute myeloid leukemia in complete remission at high risk for early relapse","volume":"124","author":"Roboz","year":"2014","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1182\/blood.V126.23.3819.3819","article-title":"Minimal residual disease (MRD) as exploratory endpoint in a phase I study of the anti-CD123 mAb CSL362 given as post-remission therapy in adult myeloid leukemia","volume":"126","author":"Smith","year":"2015","journal-title":"Blood"},{"key":"ref_127","first-page":"215549","article-title":"Single agent Talocutuzumab in elderly high-risk MDS or AML patients failing hypomethylating agents\u2013results of the SAMBA study by the EMSCO network","volume":"16","author":"Platzebecker","year":"2019","journal-title":"EHA Learning Center"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1182\/blood-2018-99-113112","article-title":"Anti-CD123 targeted therapy with Talacotuzumab in advanced MDS and AML after failing hypomethylating agents-final results of the Samba trial","volume":"132","author":"Kubasch","year":"2018","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41408-018-0168-2","article-title":"Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6\/PLD-1","volume":"9","author":"Ernst","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A CD123 targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells","volume":"2","author":"Kovtun","year":"2018","journal-title":"Blood Adv."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Evanns, K., El-Zein, N., Jones, C., Erickson, S.W., Guo, Y., Teichjer, B.A., Adams, S., Zweilder-McKay, P.A., Smith, M.A., and Lock, R.B. (2019). Abstract 4820: Pediatric preclinical testing consortium evaluation of the CD123 antibody drug conjugate, IMGN632, against xenograft models of pediatric acute lymphoblastic leukemia. Cancer Res., 79.","DOI":"10.1158\/1538-7445.SABCS18-4820"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"abst. 3956","DOI":"10.1182\/blood-2018-99-116771","article-title":"Pre-clinical efficacy of CD123-tergeting antibody-drug conjugate IMGN632 in blastic plasmocytoid dendritic cell neoplasm (BPDCN) models","volume":"132","author":"Zhang","year":"2018","journal-title":"Blood"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1182\/blood-2018-99-117214","article-title":"Synergistic anti-leukemic activity of PARP inhibition combined with IMGN632, an anti-CD123 antibody-drug conjugate in acute myeloid leukemia models","volume":"132","author":"Fritz","year":"2018","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"abst. 27","DOI":"10.1182\/blood-2018-99-112955","article-title":"A phase I, First-in-human study evaluating the safety and preliminary antileukemia activity of IMGN632, a novel CD123-tergeting antibody-drug conjugate, in patients with relapsed\/refractory acute myeloid leukemia and other CD123-positive hematologic malignancies","volume":"132","author":"Daver","year":"2018","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1097\/01.HS9.0000559020.72361.fa","article-title":"The combination of IMGN362, a CD123 targeting-ADC, with venetoclax augments anti-leukemic activity in vitro and prolongs survival in vivo in preclinic al models of human AML","volume":"3","author":"Adams","year":"2019","journal-title":"HemaSphere"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/protein\/gzs040","article-title":"Engineering of a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells","volume":"25","author":"Kuo","year":"2012","journal-title":"Protein Eng. Des. Sel."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood.V122.21.360.360","article-title":"Targeting CD123 in leukemic stem cells using dual affinity re-targeting molecules (DARTs)","volume":"122","author":"Hussaini","year":"2013","journal-title":"Blood"},{"key":"ref_138","first-page":"289ra82","article-title":"A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates","volume":"7","author":"Chicili","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood-2014-05-575704","article-title":"Targeting CD123 in acute myeloid leukemia using a T-cell directed dual affinity retargeting platform","volume":"127","author":"Rettig","year":"2016","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"abst. 764","DOI":"10.1182\/blood-2018-99-117085","article-title":"Phase 1 cohort expansion of Flotetuzumab, a CD123xCD3 bispecific DART protein in patients with relapsed\/refractory acute myeloid leukemia (AML)","volume":"132","author":"Uy","year":"2018","journal-title":"Blood"},{"key":"ref_141","first-page":"3942","article-title":"Immune gene expression profiling in children and adults with acute myeloid leukemia identifies distinct phenotypic patterns","volume":"130","author":"Vadakekolathu","year":"2017","journal-title":"Blood"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e444","DOI":"10.1182\/blood-2018-99-111539","article-title":"Adaptive immune gene signatures correlate with response to Flotetuzumab, a CD123xCD3 bispecific DART molecule, in patients with relapsed\/refractory acute myeloid leukemia","volume":"132","author":"Rutella","year":"2018","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1182\/blood-2018-99-112615","article-title":"Management of cytokine release syndrome in AML patients treated with Flotetuzumab, a CD123xCD3 bispecific DART molecule for T-cell redirected therapy","volume":"132","author":"Jacobs","year":"2018","journal-title":"Blood"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"5230","DOI":"10.1182\/blood-2018-99-116264","article-title":"A next-generation Fc-bearing CD3-engaging bispecific DART platform with extended pharmacokinetic and expanded pharmacologic window: Characterization as CD123xCD3 and CD19xCD3 DART molecules","volume":"132","author":"Bonivini","year":"2018","journal-title":"Blood"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e763","DOI":"10.1182\/blood-2018-99-119786","article-title":"Complete responses in relapsed7refractory acute myeloid leukemia (AML) patients on a weekly dosing schedule of XmAb 14045, a CD123xCD3 T cell-engaging bispecific antibody: Initial results of a phase 1 study","volume":"132","author":"Ravandi","year":"2018","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e1472195","DOI":"10.1080\/2162402X.2018.1472195","article-title":"Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells","volume":"7","author":"Braciak","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Hoffmann, S., Schubert, M.L., Wang, L., He, B., Neuber, B., Dreger, P., Muller-Tidow, C., and Schmitt, M. (2019). Chimeric antigen receptor (CAR) T cell therapy in acute myeloid leukemia (AML). J. Clin. Med., 8.","DOI":"10.3390\/jcm8020200"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3324\/haematol.2018.208751","article-title":"Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: How close to reality?","volume":"104","author":"Cummins","year":"2019","journal-title":"Haematologica"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/bjh.12282","article-title":"Targeting of acute myeloid leukemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor","volume":"161","author":"Tettamanti","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo","volume":"28","author":"Pizzitola","year":"2014","journal-title":"Leukemia"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","article-title":"T cells expressing CD123-specific cytolytic effector functions and anti-tumor effects against human acute myeloid leukemia","volume":"122","author":"Mardiros","year":"2013","journal-title":"Blood"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/imr.12774","article-title":"Updates on CAR T-cell therapy in B-cell malignancies","volume":"290","author":"Jacoby","year":"2019","journal-title":"Immunol. Rev."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2016-08-736041","article-title":"Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia","volume":"129","author":"Tasian","year":"2017","journal-title":"Blood"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.ymthe.2017.04.017","article-title":"Balance of anti-CD123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid leukemia","volume":"25","author":"Arcangeli","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1038\/s41375-019-0417-9","article-title":"Constitutively active MyD88\/CD40 costimulation enhances expansion and efficacy of chimeric antigen T cells targeting hematological malignancies","volume":"33","author":"Chang","year":"2019","journal-title":"Leukemia"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41375-018-0075-3","article-title":"Compound CART-cells as a double-pronged approach for treating acute myeloid leukemia","volume":"32","author":"Petrov","year":"2018","journal-title":"Leukemia"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1089\/hum.2017.157","article-title":"Optimization of human NK cell manufacturing: Fully automated separation, improved ex vivo expansion using IL-21 with autologous feeder cells, and generation of anti-CD123-CAR-expressing effector cells","volume":"28","author":"Klob","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1182\/blood.V126.23.3778.3778","article-title":"First-in-manCD123-spedific chimeric antigen receptor-modified T cells for the treatment of refractory acute myeloid leukemia","volume":"126","author":"Luo","year":"2015","journal-title":"Blood"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V130.Suppl_1.811.811","article-title":"Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-specific CART cells: A first-in-human clinical trial","volume":"130","author":"Budde","year":"2017","journal-title":"Blood"},{"key":"ref_164","unstructured":"Budde, L.E., Schuster, S.J., and Del Real, M. (2018, January 27\u201330). CD123CAR displays clinical activity in refractory\/relapsed acute myeloid leukemia (AML) and blastic plasmocytoid dendritic cell neoplasm (BPDCN): Safety and efficacy results from a phase 1 study. Proceedings of the AACR Tumor Immunology and Immunotherapy, Miami, FL, USA."},{"key":"ref_165","first-page":"1359","article-title":"Treating relapsed\/refractory (RR) AML with biodegradable antiCD123 CAR modified T cells","volume":"130","author":"Cummins","year":"2017","journal-title":"Blood"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1182\/blood-2018-99-116811","article-title":"IL15 expressing CD123-targeted engager T-cell therapy for adult acute myeloid leukemia","volume":"132","author":"Mu","year":"2018","journal-title":"Blood"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2018-99-113288","article-title":"Late-stage preclinical characterization of switchable CD123-specifioc CAR-T for treatment of acute leukemia","volume":"132","author":"Loff","year":"2018","journal-title":"Blood"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3324\/haematol.2018.208587","article-title":"Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?","volume":"104","author":"Ball","year":"2019","journal-title":"Haematologica"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/9\/1358\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:19:42Z","timestamp":1760188782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/9\/1358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,12]]},"references-count":168,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["cancers11091358"],"URL":"https:\/\/doi.org\/10.3390\/cancers11091358","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,12]]}}}